Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04948944 · ClinicalTrials.gov registry record · NA

Frontal Stimulation to Modulate Threat Sensitivity in Anxious Depression

A NA study, sponsored by Laureate Institute for Brain Research.

Completed
Registry status
NA
Development phase
141
Enrollment target

NCT04948944: Completed NA study, sponsored by Laureate Institute for Brain Research.

NCT04948944 is a NA study that has completed, run by Laureate Institute for Brain Research. The registered enrollment target is 141 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04948944, a NA study, has completed, sponsored by Laureate Institute for Brain Research.

COMPLETED
Registry status
NA
Development phase
141 participants
Enrollment target

Study Summary

Over 50% of patients with major depressive disorder (MDD) do not respond to initial treatment and relapse is common. In particular, comorbid depression and anxiety disorders are associated with more treatment resistance. Thus, there is a great need for novel, more targeted treatments. Transcranial direct current stimulation (tDCS) is a novel intervention that can be used to causally target neural excitability and plasticity in brain regions/circuits implicated in regulating mood and anxiety and emerging evidence suggests that it reduces threat sensitivity. Here the investigators propose to use tDCS to target threat sensitivity as a core symptom of anxious depression to determine if the investigators can engage the neural circuits that are treatment targets. Following the administration of a single dose of anxiolytic or antidepressant treatment, early changes in emotional processing have been observed in healthy people and clinical groups. Among patients, acute cognitive effects - such as a reduction in threat sensitivity - have been shown to predict response to drug and behavioral treatments. Functional magnetic resonance imaging (fMRI) studies have confirmed hyperactive amygdala and/or hypoactive prefrontal activity in patients, indicating an imbalance of activity within this cortico-limbic circuit that sub-serves threat identification (amygdala) and top-down control (prefrontal). Specifically, treatments aiming to remediate prefrontal/ amygdala dysfunction could be a critical target in patients exhibiting these deficits. Several clinical trials have shown that administration of frontal cortex tDCS is a potentially effective treatment for MDD. However, underlying mechanisms of action are unclear. To meet this gap, the investigators propose an experimental medicine study (target identification and initial target engagement paths) where 141 volunteers with anxious MDD will be randomized to receive a single session of active or sham tDCS in a parallel design. Threat s

Primary Outcome

Preliminary findings show that frontal tDCS can reduce amygdala threat reactivity in high trait anxious females. The investigators seek to replicate this effect in a larger, clinical sample which also includes males. Specifically, the investigators expect that, compared to sham tDCS, the active tDCS group will show changed amygdala BOLD fMRI activation to fearful faces (difference between fearful and neutral faces), following acute tDCS administration.

Interventions

  • DEVICE transcranial direct current stimulation

Trial Details

FieldValue
Enrollment Target 141 participants
Start Date 2021-04-13
Est. Completion 2023-10-26
Phase NA

What the finished NCT04948944 record still lists

NCT04948944 is an interventional study that assigns participants to a tested intervention. The registered 141 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).

The record links to 0 conditions, and to 1 intervention - of which transcranial direct current stimulation is the first listed.

NCT04948944 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04948944 about?

NCT04948944 is a clinical study titled "Frontal Stimulation to Modulate Threat Sensitivity in Anxious Depression". Over 50% of patients with major depressive disorder (MDD) do not respond to initial treatment and relapse is common. In particular, comorbid depression and anxiety disorders are associated with more treatment resistance. Thus, there is a great need for novel, more targeted treatments. Transcranial d...

What is the current status of trial NCT04948944?

This trial is currently completed. It is a NA study. The enrollment target is 141 participants. The study started on 2021-04-13. Estimated completion is 2023-10-26.

What interventions are being tested in trial NCT04948944?

The interventions under investigation include: transcranial direct current stimulation (DEVICE).

Who is sponsoring clinical trial NCT04948944?

This trial is sponsored by Laureate Institute for Brain Research, which has 45 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04948944's enrollment target sits among peer trials

141 712th of 2000 higher than 1,288 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03042962 · 141 participants

    Brain Networks in Dystonia

  • NCT04378439 · 141 participants · NA

    Appalachian Partnership to Reduce Disparities (Aim 2)

  • NCT04775485 · 141 participants · Phase 2

    A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

  • NCT05040360 · 141 participants · Phase 2

    Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04948944, the US trial registry maintained by the National Library of Medicine. NCT04948944 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.